Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 3/20 | 0.45 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598809 | 0.88 | NOX4 (0.45) | NOX4GPR18CDK4CCND1ALDH1A1 | |
| SCHEMBL13980201 | 0.85 | NOX4 (0.42) | NOX4CDK4CCND1ALDH1A1L3MBTL1 | |
| SCHEMBL3612980 | 0.74 | NOX4 (0.42) | NOX4ALDH1A1L3MBTL1 | |
| SCHEMBL3612480 | 0.74 | NOX4 (0.70) | NOX4L3MBTL1RAB9A | |
| SCHEMBL9976093 | 0.70 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL19608027 | 0.69 | NOX4 (0.48) | NOX4 | |
| SCHEMBL13503058 | 0.68 | NOX4 (0.40) | NOX4GPR18CDK4CCND1ALDH1A1 | |
| SCHEMBL19607842 | 0.67 | NOX4 (0.59) | NOX4ALDH1A1 | |
| SCHEMBL19607961 | 0.67 | NOX4 (0.58) | NOX4ALDH1A1L3MBTL1 | |
| SCHEMBL9975961 | 0.63 | P2RX4 (0.52) | ALDH1A1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | claimed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | claimed |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2013-05-16 | — | — | US | claimed |
| US-8389518-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-03-05 | — | — | US | claimed |
| EP-2545918-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2139477-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2012-12-12 | — | — | EP | claimed |
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-02-25 | — | — | US | claimed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9073919-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-07-07 | — | — | US | disclosed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-2545918-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-08-06 | — | — | EP | disclosed |
| EP-1553074-B1 | FUSED BENZENE DERIVATIVE AND USE | TAKEDA PHARMACEUTICAL (JP) | 2014-06-18 | — | — | EP | disclosed |
| US-7649001-B2 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| EP-2139477-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| EP-2002835-A1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GenKyo Tex (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113856-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20060106067-A1 | Fused benzene derivative and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1553074-A1 | FUSED BENZENE DERIVATIVE AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048560-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885GPR18 2106/4885PTGS1 251/4885 |
| US-20060106067-A1 | Fused benzene derivative and use | AR, NR5A1, CBR3 | NOX4 75/4885GPR18 378/4885PTGS1 2251/4885 |
| US-20130123256-A1 | Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, CYBB | NOX4 2/4885GPR18 2106/4885PTGS1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.